Patent intelligence · US
US 11951121
Compositions and methods for treating Huntington's disease
Compositions and methods for treating Huntington's disease
Patent details — US 11951121
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 9, 2024
- Expiration
- Apr 4, 2044
- Applicant
- VOYAGER THERAPEUTICS, INC.
- Claims
- 29
- CPC classes
- A61K, A61K31/7105, A61K31/713, A61K48/0025
Quick answer
US 11951121 (Compositions and methods for treating Huntington's disease) is held by VOYAGER THERAPEUTICS, INC.. Status: granted. Granted Apr 9, 2024. Expires Apr 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- VOYAGER THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K31/7105, A61K31/713, A61K48/0025, A61K48/005, A61P
More from VOYAGER THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12419969
AAV capsid variants and uses thereof
granted -
US 12319929
Compositions and methods for the treatment of Parkinson's disease
granted -
US 12305189
Compositions and methods for delivery of AAV
granted -
US 12296025
AAV capsid variants and uses thereof
granted -
US 12291565
Tau binding compounds
granted -
US 12281321
Frataxin expression constructs having engineered promoters and methods of use thereof
granted -
US 12252703
Closed-ended linear duplex DNA for non-viral gene transfer
granted -
US 12146150
Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
granted
Frequently asked questions
What is US patent 11951121?
US 11951121 (Compositions and methods for treating Huntington's disease) is held by VOYAGER THERAPEUTICS, INC.. Status: granted. Granted Apr 9, 2024. Expires Apr 4, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11951121?
VOYAGER THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 31 pharmaceutical patents for this assignee.
When does US 11951121 expire?
Our index shows an expiration date of Apr 4, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.